Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling
- PMID: 31073190
- PMCID: PMC6509164
- DOI: 10.1038/s41598-019-43638-0
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling
Abstract
Systemic Sclerosis (SSc) is a disease with limited therapeutic possibilities. Mesenchymal stem cells (MSCs)-therapy could be a promising therapeutic option, however the ideal MSCs source has not yet been found. To address this problem, we perform comparison between bone marrow (BM)-MSCs and adipose (A)-MSCs, by the miRs expression profile, to identify the gene modulation in these two MSCs source. MicroRNAs (miRs) are RNAs sequences, regulating gene expression and MSCs, derived from different tissues, may differently respond to the SSc microenvironment. The miRs array was used for the miRs profiling and by DIANA-mirPath tool we identified the biological functions of the dysregulated miRs. In SSc-BM-MSCs, 6 miRs were significantly down-regulated and 4 miRs up-regulated. In SSc-A-MSCs, 11 miRs were significantly down-regulated and 3 miRs up-regulated. Interestingly, in both the sources, the involved pathways included the senescence mechanisms and the pro-fibrotic behaviour. Furthermore, both the MSCs sources showed potential compensatory ability. A deeper knowledge of this miRs signature might give more information about some pathogenic steps of the disease and in the same time clarify the possible therapeutic role of autologous MSCs in the regenerative therapy in SSc.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis.PLoS One. 2016 Apr 7;11(4):e0153101. doi: 10.1371/journal.pone.0153101. eCollection 2016. PLoS One. 2016. PMID: 27054717 Free PMC article.
-
Comparative analysis and characterization of soluble factors and exosomes from cultured adipose tissue and bone marrow mesenchymal stem cells in canine species.Vet Immunol Immunopathol. 2019 Feb;208:6-15. doi: 10.1016/j.vetimm.2018.12.003. Epub 2018 Dec 18. Vet Immunol Immunopathol. 2019. PMID: 30712794
-
RNA-sequencing reveals positional memory of multipotent mesenchymal stromal cells from oral and maxillofacial tissue transcriptomes.BMC Genomics. 2020 Jun 22;21(1):417. doi: 10.1186/s12864-020-06825-2. BMC Genomics. 2020. PMID: 32571211 Free PMC article.
-
Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?Front Immunol. 2018 Dec 14;9:2938. doi: 10.3389/fimmu.2018.02938. eCollection 2018. Front Immunol. 2018. PMID: 30619298 Free PMC article. Review.
-
Single-Cell Profiles and Clinically Useful Properties of Human Mesenchymal Stem Cells of Adipose and Bone Marrow Origin.Am J Sports Med. 2019 Jun;47(7):1722-1733. doi: 10.1177/0363546519848678. Epub 2019 May 17. Am J Sports Med. 2019. PMID: 31100005 Review.
Cited by
-
Allogeneic mesenchymal stromal cell transplantation for systemic sclerosis.Lancet Rheumatol. 2022 Feb;4(2):e74-e75. doi: 10.1016/S2665-9913(21)00388-X. Epub 2022 Jan 5. Lancet Rheumatol. 2022. PMID: 38288739 Free PMC article. No abstract available.
-
Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches.Cells. 2022 Oct 24;11(21):3346. doi: 10.3390/cells11213346. Cells. 2022. PMID: 36359742 Free PMC article. Review.
-
Stem cell therapy in systemic sclerosis.Clin Rheumatol. 2025 Aug;44(8):3139-3151. doi: 10.1007/s10067-025-07557-y. Epub 2025 Jul 2. Clin Rheumatol. 2025. PMID: 40601079 Free PMC article. Review.
-
Impact and Possible Mechanism(s) of Adipose Tissue-Derived Mesenchymal Stem Cells on T-Cell Proliferation in Patients With Rheumatic Disease.Front Physiol. 2022 Jan 13;12:749481. doi: 10.3389/fphys.2021.749481. eCollection 2021. Front Physiol. 2022. PMID: 35095547 Free PMC article.
-
Endothelial-to-mesenchymal transition in systemic sclerosis.Clin Exp Immunol. 2021 Jul;205(1):12-27. doi: 10.1111/cei.13599. Epub 2021 Apr 18. Clin Exp Immunol. 2021. PMID: 33772754 Free PMC article. Review.
References
-
- Di Benedetto P, et al. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. Arthritis Res Ther. 2018;20:223. doi: 10.1186/s13075-018-1719-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical